Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy-Reference-Cited by-同舟云学术

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Published:2015-03-18 Issue:279 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Leverson Joel D.¹,Phillips Darren C.¹,Mitten Michael J.¹,Boghaert Erwin R.¹,Diaz Dolores²,Tahir Stephen K.¹,Belmont Lisa D.²,Nimmer Paul¹,Xiao Yu¹,Ma Xiaoju Max²,Lowes Kym N.³⁴,Kovar Peter¹,Chen Jun¹,Jin Sha¹,Smith Morey¹,Xue John¹,Zhang Haichao¹,Oleksijew Anatol¹,Magoc Terrance J.¹,Vaidya Kedar S.¹,Albert Daniel H.¹,Tarrant Jacqueline M.²,La Nghi²,Wang Le¹,Tao Zhi-Fu¹,Wendt Michael D.¹,Sampath Deepak²,Rosenberg Saul H.¹,Tse Chris¹,S. Huang David C.³⁴,Fairbrother Wayne J.²,Elmore Steven W.¹,Souers Andrew J.¹

Affiliation:

1. AbbVie Inc., North Chicago, IL 60064, USA.

2. Genentech Inc., South San Francisco, CA 94080, USA.

3. Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

4. Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

Abstract

Selective inhibition of BCL-X L synergizes with docetaxel to inhibit the growth of solid tumors but does not inhibit granulopoiesis.

Funder

Leukemia and Lymphoma Society

Medical Research Council

Australian Cancer Research Foundation

Cancer Council Victoria